financetom
Business
financetom
/
Business
/
Enhabit Q4 Earnings, Revenue Decline; Issues Outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Enhabit Q4 Earnings, Revenue Decline; Issues Outlook
Mar 5, 2025 2:21 PM

05:06 PM EST, 03/05/2025 (MT Newswires) -- Enhabit ( EHAB ) reported Q4 adjusted earnings late Wednesday of $0.04 per diluted share, down from $0.06 a year earlier.

Net service revenue for the quarter ended Dec. 31 was $258.2 million, compared with $260.6 million a year earlier.

Analysts surveyed by FactSet expected $259.1 million.

The company said it expects full-year 2025 adjusted EPS of $0.41 to $0.51 on revenue of $1.05 billion to $1.08 billion. Analysts expected $1.07 billion for revenue.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
89bio Insider Sold Shares Worth $575,153, According to a Recent SEC Filing
89bio Insider Sold Shares Worth $575,153, According to a Recent SEC Filing
Apr 3, 2024
04:07 PM EDT, 04/03/2024 (MT Newswires) -- Rohan Palekar, Director, Chief Executive Officer, on April 01, 2024, sold 52,718 shares in 89bio (ETNB) for $575,153. Following the Form 4 filing with the SEC, Palekar has control over a total of 459,171 shares of the company, with 459,171 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1785173/000095017024041024/xslF345X03/ownership.xml ...
Eli Lilly Struggles To Keep Pace With Mounjaro, Zepbound Demand: 'Currently Unavailable' On Amazon Pharmacy
Eli Lilly Struggles To Keep Pace With Mounjaro, Zepbound Demand: 'Currently Unavailable' On Amazon Pharmacy
Apr 3, 2024
After a blistering performance based on the success of its weight-loss treatments Mounjaro and Zepbound, Eli Lilly & Company stock has been trading sideways for the last five weeks as the company struggles to keep pace with demand for the drugs. Eli Lilly ( LLY ) shares have climbed 162% since the launch of Mounjaro in May 2022. Since mid-February,...
Gyre Therapeutics Insider Sold Shares Worth $323,000, According to a Recent SEC Filing
Gyre Therapeutics Insider Sold Shares Worth $323,000, According to a Recent SEC Filing
Apr 3, 2024
04:06 PM EDT, 04/03/2024 (MT Newswires) -- Nassim Usman, Director, on April 01, 2024, sold 20,000 shares in Gyre Therapeutics ( GYRE ) for $323,000. Following the Form 4 filing with the SEC, Usman has control over a total of 2,276 shares of the company, with 1,636 shares held directly and 640 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1124105/000114036124017566/xslF345X03/form4.xml ...
Cvd Equipment Insider Bought Shares Worth $1,084,162, According to a Recent SEC Filing
Cvd Equipment Insider Bought Shares Worth $1,084,162, According to a Recent SEC Filing
Apr 3, 2024
04:06 PM EDT, 04/03/2024 (MT Newswires) -- Andrew Africk, 10% Owner, on April 01, 2024, executed a purchase for 217,554 shares in Cvd Equipment ( CVV ) for $1,084,162. Following the Form 4 filing with the SEC, Africk has control over a total of 1,248,082 shares of the company, with 1,248,082 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/766792/000110465924043084/xslF345X03/tm2410979-1_4seq1.xml Price: 6.13, Change: +0.32,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved